- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07943052
Intrauterine Misoprostol in Cesarean Delivery: Effect on Postpartum Hemorrhage
Evaluation of the Efficacy of Intrauterine Misoprostol Administration on Postpartum Hemorrhage in Cesarean Operations
This prospective, randomized, controlled, two-arm study evaluates whether adding intrauterine (uterine cornual) misoprostol 400 mcg to standard oxytocin reduces postpartum blood loss in term women undergoing elective cesarean delivery. Participants are randomized 1:1 to standard oxytocin alone or standard oxytocin plus misoprostol. The primary outcome is the change in hemoglobin and hematocrit from preoperative values to 6, 24 and 48 hours after surgery.
연구 개요
상세 설명
A total of 142 women (71 per group) will be enrolled. The study group receives standard oxytocin plus a single 400 mcg dose of misoprostol placed in the uterine cornual region after placental delivery; the control group receives standard oxytocin only. Hemoglobin and hematocrit are measured before surgery and at 6, 24 and 48 hours afterwards, and participants are seen on postoperative day 10 for late complications and adverse events. The surgical team is not masked; participants are not informed of their allocation. An interim safety analysis is planned after 50 participants.
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: Halil Gümüş, MD
- 전화번호: +90 537 673 47 49
- 이메일: dr.halil.gumusrc@gmail.com
연구 장소
-
-
-
Istanbul, 터키 (Türkiye)
- Bagcilar Training and Research Hospital, Department of Obstetrics and Gynecology
-
연락하다:
- Halil Gümüş, MD
- 전화번호: +90 537 673 47 49
- 이메일: dr.halil.gumusrc@gmail.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 18-45 years
- Term pregnancy (37 weeks or more)
- Elective cesarean section planned
- ASA I-II
- Written informed consent signed
Exclusion Criteria:
- History of coagulopathy or active bleeding disorder
- Anticoagulant use
- Hemoglobin < 10 g/dL
- Active thromboembolic disease
- Severe hepatic failure
- BMI > 35 kg/m2
- Type 1 diabetes with diabetic nephropathy
- Chronic hypertension
- Gestational hypertension, preeclampsia, eclampsia or HELLP syndrome
- Placenta previa, placental abruption or placental pathology with high bleeding risk
- Multiple pregnancy
- Uterine anomalies
- Intrauterine fetal death
- Epilepsy (diagnosis or history)
- Active malignancy
- Known hypersensitivity to prostaglandins
- Refusal or withdrawal of consent
- Emergency-indicated cesarean sections (including those planned as elective but performed for fetal distress, uterine rupture or other emergency indications)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Misoprostol plus standard oxytocin
Standard oxytocin plus a single 400 mcg dose of misoprostol placed in the uterine cornual region after delivery of the placenta during elective cesarean delivery. |
Misoprostol 400 mcg (2 x 200 mcg tablets), single dose placed in the uterine cornual region after delivery of the placenta, in addition to standard oxytocin. Standard oxytocin administered after delivery of the baby according to routine clinical practice (standard of care in both arms). |
|
활성 비교기: Standard oxytocin
Standard oxytocin only, according to routine clinical practice, during elective cesarean delivery. |
Standard oxytocin administered after delivery of the baby according to routine clinical practice (standard of care in both arms). |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in hemoglobin from preoperative value to postoperative 6, 24 and 48 hours
기간: Preoperative, and 6, 24 and 48 hours after surgery
|
Hemoglobin (g/dL) measured before surgery and at 6, 24 and 48 hours after surgery; change from the preoperative value is compared between groups. |
Preoperative, and 6, 24 and 48 hours after surgery
|
|
Change in hematocrit from preoperative value to postoperative 6, 24 and 48 hours
기간: Preoperative, and 6, 24 and 48 hours after surgery
|
Hematocrit (%) measured before surgery and at 6, 24 and 48 hours after surgery; change from the preoperative value is compared between groups. |
Preoperative, and 6, 24 and 48 hours after surgery
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Need for blood transfusion
기간: From surgery until hospital discharge, up to 48 hours
|
Proportion of participants requiring blood transfusion after surgery. |
From surgery until hospital discharge, up to 48 hours
|
|
Need for additional uterotonic or hemostatic intervention
기간: During surgery and until hospital discharge, up to 48 hours
|
Proportion of participants requiring additional uterotonic agents or other hemostatic interventions. |
During surgery and until hospital discharge, up to 48 hours
|
|
Late postoperative complications and readmission
기간: Up to postoperative day 10
|
Late complications and hospital readmission assessed at the postoperative day 10 visit. |
Up to postoperative day 10
|
|
Misoprostol-related adverse events
기간: Up to postoperative day 10
|
Adverse events potentially related to misoprostol (e.g., fever, shivering, nausea, vomiting, diarrhea) recorded in both groups. |
Up to postoperative day 10
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Cem Yener, MD, Associate Professor, Bagcilar Training and Research Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- E-66291034-50.04-7274
- 248 (기타 식별자: Istanbul Medipol University Clinical Research Ethics Committee)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .